Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
24.26
+0.29 (1.21%)
At close: Nov 10, 2025, 4:00 PM EST
24.22
-0.04 (-0.16%)
After-hours: Nov 10, 2025, 7:59 PM EST
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 36,830 employees as of December 31, 2024. The number of employees decreased by 1,021 or -2.70% compared to the previous year.
Employees
36,830
Change (1Y)
-1,021
Growth (1Y)
-2.70%
Revenue / Employee
$455,498
Profits / Employee
$19,359
Market Cap
27.83B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36,830 | -1,021 | -2.70% |
| Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
| Dec 31, 2022 | 36,826 | -711 | -1.89% |
| Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
| Dec 31, 2020 | 40,216 | 177 | 0.44% |
| Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
| Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
| Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
| Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
| Dec 31, 2015 | 42,888 | -121 | -0.28% |
| Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
| Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
| Dec 31, 2012 | 45,948 | 194 | 0.42% |
| Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
| Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
| Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
| Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
| Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
| Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
| Dec 31, 2005 | 14,698 | 885 | 6.41% |
| Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
| Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
| Dec 31, 2002 | 9,577 | 591 | 6.58% |
| Dec 31, 2001 | 8,986 | 361 | 4.19% |
| Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TEVA News
- 11 hours ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 days ago - AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living - GlobeNewsWire
- 5 days ago - Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Benzinga
- 5 days ago - Teva Pharmaceuticals stock surges 12% as branded drug sales outperform - Invezz
- 5 days ago - Teva Pharm third-quarter profit tops estimates as branded drugs gain - Reuters
- 5 days ago - Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS - GlobeNewsWire
- 10 days ago - Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - GlobeNewsWire